Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Enterobacteriaceae- related urinary tract infections
Introduction: We aimed to demonstrate if fosfomycin tromethamine (FT) treatment could be the treatment of choice in ESBL-producing Enterobacteriaceae strains as an alternative to carbapenem particularly in patients who we would like to treat on an outpatient basis. Methodology; We retrospectivel...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2019-01-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/10658 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850147963827912704 |
|---|---|
| author | Ayhanim Tumturk Senol Tonyali Ayse Yasemin Tezer Tekce Levent Isikay Hakan Cime |
| author_facet | Ayhanim Tumturk Senol Tonyali Ayse Yasemin Tezer Tekce Levent Isikay Hakan Cime |
| author_sort | Ayhanim Tumturk |
| collection | DOAJ |
| description |
Introduction: We aimed to demonstrate if fosfomycin tromethamine (FT) treatment could be the treatment of choice in ESBL-producing Enterobacteriaceae strains as an alternative to carbapenem particularly in patients who we would like to treat on an outpatient basis.
Methodology; We retrospectively analyzed the medical records of all patients who admitted to infectious disease outpatient clinic with complaints of dysuria and frequency and received FT for lower UTI between May 2016 and May 2017.
Results: A total of 48 patients, 19 females (39.6%) and 29 males (60.4%), with a mean age of 62.5 (ranging from 27 to 85) years were included the study. 26 (76.4%) of patients with a history of urinary operation or intervention had also a history of antibiotic use within the past 3 months. The isolated pathogens included Escherichia Coli (n = 32), Klebsiella spp. (n = 12), Enterobacter spp. (n = 4). The overall microbiological response after treatment was 70.8% (34/48) and the clinical response was 75% (36/48). Clinical and microbiological response rates of patients with and without urinary operation/intervention, diabetes mellitus, history of antibiotic use and malignancy were found similar (p > 0.05). However, patients with a urinary stone disease history had significantly higher response rates than those without a urinary stone disease history (P = 0.042).
Conclusion: Oral fosfomycin tromethamine might be the treatment of choice in ESBL-producing enterobactericea related UTIs especially caused by Escherichia Coli.
|
| format | Article |
| id | doaj-art-8580c395dd254bddaae9eee22e8ca755 |
| institution | OA Journals |
| issn | 1972-2680 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-8580c395dd254bddaae9eee22e8ca7552025-08-20T02:27:23ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802019-01-01130110.3855/jidc.10658Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Enterobacteriaceae- related urinary tract infectionsAyhanim Tumturk0Senol Tonyali1Ayse Yasemin Tezer Tekce2Levent Isikay3Hakan Cime4University of Health Sciences, Clinic of Infectious Diseases, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, TurkeyUniversity of Health Sciences, Clinic of Urology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, TurkeyUniversity of Health Sciences, Clinic of Infectious Diseases, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, TurkeyUniversity of Health Sciences, Clinic of Urology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, TurkeyUniversity of Health Sciences, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey Introduction: We aimed to demonstrate if fosfomycin tromethamine (FT) treatment could be the treatment of choice in ESBL-producing Enterobacteriaceae strains as an alternative to carbapenem particularly in patients who we would like to treat on an outpatient basis. Methodology; We retrospectively analyzed the medical records of all patients who admitted to infectious disease outpatient clinic with complaints of dysuria and frequency and received FT for lower UTI between May 2016 and May 2017. Results: A total of 48 patients, 19 females (39.6%) and 29 males (60.4%), with a mean age of 62.5 (ranging from 27 to 85) years were included the study. 26 (76.4%) of patients with a history of urinary operation or intervention had also a history of antibiotic use within the past 3 months. The isolated pathogens included Escherichia Coli (n = 32), Klebsiella spp. (n = 12), Enterobacter spp. (n = 4). The overall microbiological response after treatment was 70.8% (34/48) and the clinical response was 75% (36/48). Clinical and microbiological response rates of patients with and without urinary operation/intervention, diabetes mellitus, history of antibiotic use and malignancy were found similar (p > 0.05). However, patients with a urinary stone disease history had significantly higher response rates than those without a urinary stone disease history (P = 0.042). Conclusion: Oral fosfomycin tromethamine might be the treatment of choice in ESBL-producing enterobactericea related UTIs especially caused by Escherichia Coli. https://jidc.org/index.php/journal/article/view/10658urinary tract infectionfosfomycinenterobacteriaceaeEscherichia coliklebsiellla |
| spellingShingle | Ayhanim Tumturk Senol Tonyali Ayse Yasemin Tezer Tekce Levent Isikay Hakan Cime Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Enterobacteriaceae- related urinary tract infections Journal of Infection in Developing Countries urinary tract infection fosfomycin enterobacteriaceae Escherichia coli klebsiellla |
| title | Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Enterobacteriaceae- related urinary tract infections |
| title_full | Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Enterobacteriaceae- related urinary tract infections |
| title_fullStr | Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Enterobacteriaceae- related urinary tract infections |
| title_full_unstemmed | Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Enterobacteriaceae- related urinary tract infections |
| title_short | Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Enterobacteriaceae- related urinary tract infections |
| title_sort | fosfomycin in the treatment of extended spectrum beta lactamase producing enterobacteriaceae related urinary tract infections |
| topic | urinary tract infection fosfomycin enterobacteriaceae Escherichia coli klebsiellla |
| url | https://jidc.org/index.php/journal/article/view/10658 |
| work_keys_str_mv | AT ayhanimtumturk fosfomycininthetreatmentofextendedspectrumbetalactamaseproducingenterobacteriaceaerelatedurinarytractinfections AT senoltonyali fosfomycininthetreatmentofextendedspectrumbetalactamaseproducingenterobacteriaceaerelatedurinarytractinfections AT ayseyasemintezertekce fosfomycininthetreatmentofextendedspectrumbetalactamaseproducingenterobacteriaceaerelatedurinarytractinfections AT leventisikay fosfomycininthetreatmentofextendedspectrumbetalactamaseproducingenterobacteriaceaerelatedurinarytractinfections AT hakancime fosfomycininthetreatmentofextendedspectrumbetalactamaseproducingenterobacteriaceaerelatedurinarytractinfections |